Wet Age-Related Macular Degeneration

Patient education, intervention and appropriate referrals are important to consider in older adults with glaucoma, according to findings published in the American Journal of Ophthalmology.

Topline results from an open-label safety study investigating ONS-5010/Lytenava in the treatment of retinal diseases showed no unexpected safety results, according to a press release from Outlook Therapeutics.

Researchers in Spain identified and recommended patient-reported outcome measures for clinical use in individuals with age-related macular degeneration or diabetic retinopathy in a new study.

In this special episode, I sit down with this week’s co-host, my wife Yasmin P. Mali, MD, to discuss my top 5 predictions in ophthalmology in the new year. Stay tuned for a special announcement at the end of the show.

The U.K. National Institute for Health and Care Excellence has issued a final appraisal determination recommending Novartis’ brolucizumab treatment for wet age-related macular degeneration.

Despite the COVID-19 pandemic, the FDA approved 47 new molecular entities in 2020, including one for ophthalmology, compared with 48 in 2019, according to a speaker at the virtual Ophthalmology Innovation Summit Year in Review meeting.

Two-year results of the MERLOT trial showed no benefit of epimacular brachytherapy as an adjunct to anti-VEGF injections. In fact, the combined therapy group had worse results overall compared with the ranibizumab monotherapy group.

AsclepiX Therapeutics closed $35 million in Series A financing to fund its upcoming clinical trials of AXT107 to treat various retinal diseases, according to a press release.

Patients treated with intravitreal injections of anti-high temperature requirement A1, a novel serine protease inhibitor, for the treatment of geographic atrophy experienced no serious study drug-related ocular or systemic adverse events.

The FDA approved a label update for Beovu to include safety information about retinal vasculitis and retinal vascular occlusion, according to a Novartis press release.